^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/28/2023
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers...SQUAMOUS CELL CARCINOMA….Useful in Certain Circumstances:...Selpercatinib for RET gene fusion-positive tumors